<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordsOutput xmlns:ns2="local"><serviceExecutionTime>335</serviceExecutionTime><Drug id="7130"><DrugName>nateplase</DrugName><DrugNamesKey><Name id="42770635">Milyzer</Name><Name id="42770634">Tepase</Name></DrugNamesKey><DrugSynonyms><Name><Value>nateplase</Value></Name><Name><Value>Tepase</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>Milyzer</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>tPA, Mitsui</Value></Name><Name><Value>MMR-701, Mitsui</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>plasminogen activator, Mitsui</Value></Name></DrugSynonyms><CompanyOriginator id="25770">Mitsui Chemicals Inc</CompanyOriginator><CompaniesPrimary><Company id="25770">Mitsui Chemicals Inc</Company></CompaniesPrimary><CompaniesSecondary><Company id="18278">Mochida Pharmaceutical Co Ltd</Company></CompaniesSecondary><CrossReferences><SourceEntity id="7130" type="Drug"><TargetEntity id="204617" type="siDrug">Nateplase</TargetEntity></SourceEntity><SourceEntity id="18278" type="Company"><TargetEntity id="4295877793" type="organizationId">Mochida Pharmaceutical Co Ltd</TargetEntity></SourceEntity><SourceEntity id="25770" type="Company"><TargetEntity id="4295877421" type="organizationId">Mitsui Chemicals Inc</TargetEntity></SourceEntity><SourceEntity id="224" type="ciIndication"><TargetEntity id="10028596" type="MEDDRA"></TargetEntity><TargetEntity id="D009203" type="MeSH"></TargetEntity><TargetEntity id="-998451372" type="omicsDisease"></TargetEntity><TargetEntity id="226" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="L">Launched</PhaseHighest><PhaseHighestDetailed><FirstLaunched>Myocardial infarction - Japan - Aug-1996</FirstLaunched></PhaseHighestDetailed><IndicationsPrimary><Indication id="224">Myocardial infarction</Indication></IndicationsPrimary><ActionsSecondary><Action id="166">Fibrinolysis stimulator</Action><Action id="311">Plasminogen activator stimulator</Action><Action id="59620">Unspecified drug target</Action></ActionsSecondary><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="112">DNA technology</Technology><Technology id="766">Parenteral formulation unspecified</Technology><Technology id="80">Peptide</Technology></Technologies><EphmraCodes><Ephmra><Code>B1D</Code><Name>FIBRINOLYTICS</Name></Ephmra></EphmraCodes><LastModificationDate>2018-01-25T11:09:23.000Z</LastModificationDate><ChangeDateLast>2009-03-19T17:15:28.000Z</ChangeDateLast><AddedDate>1996-02-16T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;Mitsui has developed and launched &lt;ulink linkID="7130" linkType="Drug"&gt;nateplase&lt;/ulink&gt; (MMR-701, Milyzer, Tepase) a tissue plasminogen activator (t-PA) stimulator for the treatment of myocardial infarction [&lt;ulink linkID="192281" linkType="reference"&gt;192281&lt;/ulink&gt;]. In January 1994, the company filed an NDA in Japan, which in March 1996 received a recommendation for approval [&lt;ulink linkID="204424" linkType="reference"&gt;204424&lt;/ulink&gt;] and the product was launched in July 1996 [&lt;ulink linkID="227620" linkType="reference"&gt;227620&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In 1996, &lt;ulink linkID="7130" linkType="Drug"&gt;nateplase&lt;/ulink&gt; was licensed to Mochida Pharmaceutical for Japan [&lt;ulink linkID="192281" linkType="reference"&gt;192281&lt;/ulink&gt;]. In November 1996, Mochida announced its decision to withdraw from the t-PA agreement, following a patent infringement suit brought against it and Mitsui by &lt;ulink linkID="19453" linkType="Company"&gt;Genentech&lt;/ulink&gt;. The company was confident that there has been no infringement, but as the case would not be concluded for at least two to three years the company decided that it would be difficult to market the drug under such circumstances [&lt;ulink linkID="229924" linkType="reference"&gt;229924&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="25770">Mitsui Chemicals Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="224">Myocardial infarction</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1996-08-01T00:00:00.000Z</StatusDate><Source id="227620" type="SERIAL"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18278">Mochida Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="224">Myocardial infarction</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1996-11-30T00:00:00.000Z</StatusDate><Source id="227620" type="SERIAL"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="18278">Mochida Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="224">Myocardial infarction</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1994-01-01T00:00:00.000Z</StatusDate><Source id="192281" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="25770">Mitsui Chemicals Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="224">Myocardial infarction</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1994-01-01T00:00:00.000Z</StatusDate><Source id="192281" type="SERIAL"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Indexing Updated</Reason><Description>Indexing updated</Description></ReasonForUpdate><ReasonForUpdate><Reason>Deal Summary Added/Updated</Reason><Description>Licensing information updated</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="18278">Mochida Pharmaceutical Co Ltd</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="25770">Mitsui Chemicals Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>1</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>0</CountActive><CountInactive>1</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><Deals><Deal id="121818" title="Mochida to develop Mitsui Chemicals' nateplase in Japan"></Deal></Deals><PatentFamilies><PatentFamily id="1423164" number="EP-00093619" title="Human tissue plasminogen activator, pharmaceutical compositions containing it, processes for making it, and DNA and transformed cell intermediates therefor."></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="8">General interest</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sanofi SA" id="1009547"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Abbott Laboratories" id="13601"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Boehringer Ingelheim International GmbH" id="14881"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Johnson &amp; Johnson" id="17332"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Merck &amp; Co Inc" id="18077"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Mochida Pharmaceutical Co Ltd" id="18278"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Pfizer Inc" id="18767"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Roche Holding AG" id="19446"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sumitomo Chemical Co Ltd" id="20268"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Takeda Pharmaceutical Co Ltd" id="20300"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Toyobo Co Ltd" id="20426"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="UCB SA" id="20452"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Mitsui Chemicals Inc" id="25770"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="GlaxoSmithKline plc" id="28355"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></Drug></ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordsOutput>